CARotid plaqUe StabilizatiOn and Regression With Evolocumab.
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The CARUSO trial aims at investigating the efficacy of evolocumab in promoting carotid plaque
morphological stabilization and regression as compared to traditional lipid lowering therapy
(LLT). Primary end-point of the study is the superiority of evolocumab on top of ongoing LLT
versus ongoing LLT in carotid plaque morphological stabilization and regression at 6 and 12
months, respectively. Secondary end-points are: LDL-Cholesterol (LDL-C) absolute and
percentage changes in the two groups at 12 month follow-up, and adverse cerebrovascular and
cardiac events at 12 and 24 months